1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Generic Drug Opportunity Assessment : Boceprevir (Victrelis)

  • January 2014
  • Greystone Research Associates
Report ID: 1973867

Summary

Greystone Research Associates has identified a branded drug that represents an attractive opportunity for generic drug companies. Details of our findings are contained in an insightful assessment.

The Brand

Boceprevir is a direct acting antiviral drug against the hepatitis C (HCV) virus It is an inhibitor (protease inhibitor) of the HCV non-structural protein 3 (NS3) serine protease. Protease inhibitors are a class of antiviral drugs that are widely used to treat HIV/AIDS and hepatitis caused by hepatitis C virus. Protease inhibitors prevent viral replication by selectively binding to viral proteases (e.g. HIV-1 protease) and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Boceprevir (Victrelis) and the competing telaprevir (Incivek, Vertex Parmaceuticals) are indicated in combination with peginterferon plus ribavirin for genotype-1 HCV infection, the main HCV genotype worldwide.

The Market

Hepatitis C virus (HCV) is transmitted mainly by blood-to-blood contact, although it may be transmitted through unsafe sex. An estimated 3.9 million (1.8%) in the U.S. have been infected with HCV, of whom 2.7 million are chronically infected. Globally, an estimated 170 million persons are chronically infected with HCV and 3 to 4 million persons are newly infected each year.

Competitive Landscape

Incivek (telaprevir) is supplied by Vertex Pharmaceuticals. Incivek is an orally-administered HCV protease inhibitor for adults with genotype 1 HCV infection that is prescribed in combination with pegylated-interferon, or peg-IFN, and ribavirin, or RBV. Incivek was approved by the FDA, in the second quarter of 2011 and by Health Canada in the third quarter of 2011.
Incivek (telaprevir) is supplied by Vertex Pharmaceuticals. Incivek is an orally-administered HCV protease inhibitor for adults with genotype 1 HCV infection that is prescribed in combination with pegylated-interferon, or peg-IFN, and ribavirin, or RBV. Incivek was approved by the FDA, in the second quarter of 2011 and by Health Canada in the third quarter of 2011. In the third quarter of 2011, Vertex marketing partners Janssen Pharmaceutica, N.V., Mitsubishi Tanabe Pharma obtained marketing approval for telaprevir from the European Commission and the Japanese Ministry of Health, Labor and Welfare, respectively. Janssen markets telaprevir under the brand name INCIVO in Europe and other countries in its territories, and Mitsubishi Tanabe markets telaprevir under the brand name Telavic in Japan.

ANDA P (IV) Certification Activity

The antivirals segment has been one of the more active in recent years in terms of ANDA P 4 filings. There have been thirteen P (IV) patent certifications filed against branded antiviral drugs in the past three years.

The Opportunity

Competition among antivirals is quite high due to the number of alternative therapeutic drugs available and also because of the generally low level of specificity for any given drug in the treatment of a particular viral condition. As a result ANDA first-filers typically have a narrow window in which to work to produce the revenue numbers in their forecasts. In this environment, pre-launch planning and secondary sources of supply for critical materials can be critical to the success of the filing.

Generic Revenue Opportunity

We are predicting that the ANDA first-filer entering the market in will capture of the total global market for boceprevir drugs for the treatment of HCV in calendar year . The majority of sales will come during the 180-day exclusivity period, at a price approximately of the brand price.

Report Highlights

Victrelis – The Brand
Boceprevir – The Product
Boceprevir – The Market
Boceprevir – The Opportunity
Manufacturing and Sourcing
Victrelis Patents and Exclusivity
Therapeutic Class P4 Certifications
Generic First-to-File Revenue Opportunity
Business Risk Assessment
First-to-File – Probabilistic Scenario

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Chronic Liver Disease Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • June 2017
  • by GlobalData

Chronic Liver Disease Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Chronic Liver Disease Global Clinical Trials Review, H1, 2017" provides an overview of Chronic ...

Cirrhosis Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • June 2017
  • by GlobalData

Cirrhosis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Cirrhosis Global Clinical Trials Review, H1, 2017" provides an overview of Cirrhosis clinical trials scenario. ...

Global Biosimilars and Follow-On Biologics Market 2017-2027

  • $ 3247
  • Industry report
  • May 2017
  • by Visiongain

Report Details The global biosimilars and follow-on biologics market is expected to grow at a CAGR of 38.8% in the first half of the forecast period and CAGR of 11.3% in the second half of the forecast ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.